Substituted Oxysterol Compositions for Potent NMDA Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oxysterols lack improved in vivo potency, pharmacokinetic properties, oral bioavailability, formulatability, stability, and safety for modulating NMDA receptor function, which are essential for preventing and treating NMDA-mediated disorders.
Innovation Solution
Development of substituted oxysterols with specific structural modifications, such as varying alkyl groups and ring formations, to enhance potency and safety for modulating NMDA receptors, formulated into pharmaceutical compositions for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing oxysterols are used to modulate NMDA receptor function, then NMDA receptor modulation is achieved, but in vivo potency, pharmacokinetic properties, oral bioavailability, stability, and safety are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically varying the oxysterol molecular structure through different substituent groups (R1-R8) at specific positions on the steroid nucleus. This includes modifying alkyl chains, hydroxyl groups, and ring structures to optimize the balance between NMDA receptor potency and pharmacokinetic properties. The structural parameters are tuned to improve oral bioavailability and stability while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent employs composite material principles by creating oxysterol derivatives that combine the cholesterol backbone with various functional substituents. These composite structures integrate the lipid-soluble steroid nucleus with polar hydroxyl groups and variable alkyl chains, optimizing both membrane permeability and receptor binding affinity. The composite nature allows simultaneous improvement of potency, pharmacokinetics, and safety profiles.
2Reliability
If oxysterols are developed with improved potency and pharmacokinetic properties, then therapeutic effectiveness increases, but formulation complexity and manufacturing difficulty may increase
Solution Approach 1:
The patent applies local quality principles by introducing specific functional groups at predetermined positions on the oxysterol molecule. Each substituent (R1-R8) is strategically placed to provide localized properties such as enhanced metabolic stability, improved solubility, or increased receptor affinity. This localized modification approach allows optimization of pharmacokinetic properties without requiring complete restructuring of the molecule, thereby simplifying manufacturing.
3Object-affected harmful factors
If substituted oxysterols are designed to enhance safety and reduce side effects, then therapeutic index improves, but structural complexity increases
Solution Approach 1:
The patent applies the blessing in disguise principle by converting potentially harmful metabolic byproducts into beneficial structural features. By strategically placing hydroxyl groups and alkyl substituents, the design directs metabolic pathways toward safer, more stable degradation products. The structural modifications that initially increase complexity ultimately reduce toxicity and improve the therapeutic index by preventing formation of harmful metabolites.
Data Source
AI summary
Compounds are provided according to Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R6, R7, R8, and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.